BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30
• 31

• 

  Collaboration

  Novo Puts $4.6B on the Line to Expand Valo Deal, Maintain Cardiometabolic Leadership

  The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with partnerships with Photys Therapeutics, Ascendis Pharma and two Flagship-backed start-ups.

  January 8, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Opinion

  A Cautiously Sunny Outlook for Biopharma in 2025

  Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, oncology and reaping the benefits of AI.

  January 8, 2025

   · 

  4 min read

   · 

  Bryan Spielman
• 

  Neuroscience

  Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases

  Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of brain-penetrant small molecules to address inflammation, metabolic dysfunction and restoring lysosomal function.

  January 8, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Vaccines

  GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome Warnings

  A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments to the vaccines’ labels.

  January 8, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Roche Nears Completion of Poseida Acquisition Worth Up to $1.5B

  In a deal expected to close in Q1 2025, Roche will gain access to Poseida’s off-the-shelf CAR T candidates.

  January 8, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Deals

  Pharmas Turn to Licensing Deals as Risky Science Rises

  Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the biotech ecosystem? Experts weigh in.

  January 8, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Cell therapy

  Galapagos to Spin Out Innovative Medicines, Lay Off 40%

  By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell therapy company, the latter of which will inherit the Galapagos name.

  January 8, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Podcast

  NextGen Class of 2025, M&A Uptick Predicted Heading Into JPM, FDA Decisions to Watch

  BioSpace presents 25 noteworthy biopharma startups in ’25; analysts forecast stronger M&A as the J.P. Morgan Healthcare Conference kicks off next week; GLP-1s continue to expand their reach as Novo, Lilly fight against compounders; and a look ahead to five key FDA decisions in Q1.

  January 8, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Weight loss

  FDA Proposes Draft Guidance for Weight-Loss Therapies as Obesity Space Heats Up

  The FDA recommended maintaining a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of their investigational obesity candidates.

  January 8, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  IPO

  Maze Opens 2025 IPO Class to Advance Kidney Disease Programs

  Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in funding to support the development of its kidney disease pipeline.

  January 8, 2025

   · 

  2 min read

   · 

  Tristan Manalac